Preventing viral infections after stem cell transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a special type of donor immune cell (depleted of CD45RA cells) to see if it can prevent serious viral infections in people at high risk after a stem cell transplant from a half-matched donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had or will have a stem cell transplant from a half-matched donor
- You have at least one risk factor for viral infection, such as being over 50, under 14, or having a donor with different CMV or EBV status
- You must have a suitable donor available to provide the special immune cells
- Your liver, kidney, heart, and lung function must be adequate as determined by standard tests
- You cannot have severe graft-versus-host disease (GVHD) or an active viral infection at the time of treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether specially prepared donor immune cells can fight stubborn viral infections that did not get better with standard treatment. It is for people who have had a stem cell transplant and are still struggling with viruses like CMV, EBV, or others.
This early-phase study tests whether giving donor immune cells (DLI) that have been “depleted” of a specific marker (CD45RA) can lower the chance of the leukemia/lymphoma coming back after a half-matched stem cell transplant. It’s meant to be preventive, not treatment for an active relapse.
This early-phase study tests a modified immune-cell treatment given after a haploidentical stem cell transplant (using a half-matched donor). It aims to reduce the immune attack complications while still helping prevent or control blood cancer return.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This Phase 2 study tests a preventive “cell therapy” made from a donor’s immune cells to lower the risk of CMV infection after a haploidentical stem cell transplant. If you’re at risk for CMV, this may help protect you during the early post-transplant period.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.